B4GALT1

B4GALT1 is a Golgi-resident β-1,4-galactosyltransferase that transfers galactose to N-acetylglucosamine termini on N-glycans and O-glucose glycans of a broad array of substrate glycoproteins, thereby controlling their stability, trafficking, ligand-binding capacity, and signaling output. The enzyme forms catalytically silent homodimers through its active-site surface and is reactivated by heteromeric assembly with ST6GAL1 via noncatalytic charged domains, while its interaction with the UDP-galactose transporter SLC35A2 couples donor-substrate availability to Golgi glycosylation output (PMID:31395657, PMID:30352055, PMID:40230451). Through galactosylation of substrates including ApoB, fibrinogen, CETP, PD-L1, CDK11p110, integrin β1/α6, IL-1R1, LRP5/6, PPARγ, TGF-βRII, and TCR/CD8, B4GALT1 modulates lipoprotein metabolism, coagulation, immune checkpoint regulation, Wnt receptor surface presentation, inflammatory signaling, and T-cell activation (PMID:34855475, PMID:37907465, PMID:37303063, PMID:42002123, PMID:41182165, PMID:39231945). The hypomorphic p.Asn352Ser variant reduces enzymatic activity by approximately 50%, globally altering plasma glycoprotein galactosylation and sialylation and lowering LDL-cholesterol and fibrinogen levels in humans and knock-in mice, and biallelic loss-of-function mutations cause B4GALT1-CDG (congenital disorder of glycosylation) (PMID:34855475, PMID:31800099).

1. 2012 Medium

   Early functional studies established that B4GALT1 knockdown reduces membrane galactosylation and reverses multidrug resistance in leukemia, linking its enzymatic activity to drug efflux and Hedgehog signaling — demonstrating that B4GALT1 galactosylation has broad cellular consequences beyond simple glycan decoration.

   Evidence RNAi knockdown in adriamycin-resistant K562 cells with enzyme activity, lectin staining, and drug sensitivity assays

   PMID:23024026

   Open questions at the time

   • Specific glycoprotein substrates mediating resistance not identified
   • Hedgehog pathway link is correlative, direct glycosylation target unknown
2. 2018 High

   Structural determination of human B4GALT1 revealed that the enzyme exists as a homodimer in dynamic equilibrium with monomer, with open and closed conformations of the Trp loop and lid controlling substrate access — providing the first atomic-level explanation of catalytic regulation through oligomeric state.

   Evidence X-ray crystallography, targeted mutagenesis, and in vivo FRET assays

   PMID:30352055

   Open questions at the time

   • Membrane-anchored full-length structure not resolved
   • Kinetic parameters for monomer vs. dimer not quantitated
3. 2019 High

   The discovery that B4GALT1 and ST6GAL1 form Golgi heteromers via noncatalytic charged surfaces, restoring catalytic activity that is silenced in B4GALT1 homomers, established a regulatory logic in which sequential glycosyltransferases physically coordinate their activities within the Golgi.

   Evidence Molecular docking, mutagenesis screens, and high-throughput live-cell FRET

   PMID:31395657

   Open questions at the time

   • Stoichiometry and dynamics of heteromeric complexes in native Golgi not determined
   • Whether other glycosyltransferases participate in these assemblies is unknown
4. 2019 High

   Identification of integrin α6 and β1 as direct galactosylation substrates showed that B4GALT1 loss paradoxically enhances laminin binding and promotes HCC invasion, revealing that galactosylation can inhibit rather than activate integrin function.

   Evidence Mass spectrometry, GSLII lectin pulldown, B4GALT1 KO, blocking antibody rescue, NOD/SCID metastasis model

   PMID:37907465

   Open questions at the time

   • Specific N-glycan sites on integrins that mediate the laminin-binding change not mapped
   • Generalizability to other integrin heterodimers not tested
5. 2019 Medium

   Analysis of B4GALT1-CDG patients revealed that CETP is hypoglycosylated and functionally impaired, directly connecting B4GALT1 loss-of-function to altered HDL/LDL homeostasis in humans.

   Evidence Isoelectric focusing, CETP glyco-isoform Western blot, and CETP activity assay in CDG patient plasma

   PMID:31800099

   Open questions at the time

   • Small patient cohort limits statistical power
   • Whether CETP glycosylation site(s) are directly modified by B4GALT1 not mapped
6. 2020 Medium

   B4GALT1 was shown to glycosylate PD-L1 and CDK11p110, stabilizing both proteins — extending the substrate repertoire to immune checkpoint and cell-cycle regulators and implicating B4GALT1 in tumor immune evasion and chemoresistance.

   Evidence Co-IP, glycosylation assays, knockdown/overexpression in lung and pancreatic cancer models, orthotopic mouse models

   PMID:33309857 PMID:37303063

   Open questions at the time

   • In vitro reconstitution of direct galactosylation for PD-L1 and CDK11p110 not performed
   • Glycosylation sites on these substrates not mapped
7. 2021 High

   The naturally occurring p.Asn352Ser variant was demonstrated to reduce B4GALT1 enzymatic activity ~50%, globally decreasing galactosylation and sialylation of ApoB, fibrinogen, IgG, and transferrin, with recapitulation in knock-in mice — establishing B4GALT1 as a causal node for plasma lipoprotein and coagulation factor glycosylation.

   Evidence In vitro enzyme assay, human serum glycan profiling, Asn352Ser knock-in mouse

   PMID:34855475

   Open questions at the time

   • Whether reduced galactosylation of each substrate independently contributes to the clinical phenotype is unclear
   • Effects on non-N-glycan substrates not assessed
8. 2023 Medium

   Quantitative glycoproteomic profiling of N352S homozygote plasma deepened the substrate landscape, confirming broad effects on lipid metabolism, coagulation, and immune glycoproteins at the site-specific glycopeptide level.

   Evidence Nano-LC-MS/MS with TMT-labeling, quantitative proteomics and glycoproteomics

   PMID:37328064

   Open questions at the time

   • Functional consequences for each differentially glycosylated protein not individually tested
   • Tissue-specific glycosylation effects not resolved
9. 2024 Medium

   B4GALT1-dependent galactosylation of TGF-βRII was shown to enable galectin-8 binding, which competes with TGF-β to suppress EMT — revealing a mechanism by which B4GALT1 indirectly regulates TGF-β signaling through glycan-lectin interactions.

   Evidence Recombinant galectin-8 treatment, B4GALT1 depletion, co-receptor binding assays, intra-splenic injection tumor model

   PMID:39231945

   Open questions at the time

   • Direct galactosylation site on TGF-βRII not mapped
   • Whether other galectins similarly compete at B4GALT1-modified receptors is untested
10. 2025 Medium

    Multiple 2025 studies expanded the mechanistic picture: B4GALT1 retains LRP5/6 in the Golgi to regulate Wnt receptor surface availability; its loss stabilizes PPARγ to suppress ferroptosis in hepatocytes; it galactosylates IL-1R1 at N193 to promote inflammatory signaling; its interaction with SLC35A2 is regulated by UDP-Gal availability; and SPOP/NOLC1 controls its transcription — collectively demonstrating that B4GALT1 integrates metabolite sensing, transcriptional regulation, and substrate-specific glycosylation into diverse signaling outputs.

    Evidence Co-IP, surface biotinylation, hepatocyte-specific KO mice, site-directed mutagenesis (N193), NanoBiT PPI assay, ChIP/luciferase, AAV-mediated knockdown in DMM mice

    PMID:40097806 PMID:40230451 PMID:41182165 PMID:41860570 PMID:42002123

    Open questions at the time

    • Golgi retention mechanism for LRP5/6 (glycosylation-dependent vs. scaffolding) not resolved
    • Whether SLC35A2-B4GALT1 complex formation directly modulates catalytic rate is untested
    • NOLC1-dependent transcriptional activation of B4GALT1 not validated across cell types

• Key unresolved questions include the full site-specific glycosylation map for B4GALT1 substrates in different tissues, the structural basis of the B4GALT1–ST6GAL1 heteromer and B4GALT1–SLC35A2 complex, whether B4GALT1 catalytic activity versus scaffolding is required for Golgi retention of client receptors, and the in vivo consequences of selectively disrupting individual substrate glycosylation events.
• No full-length membrane-anchored structure of B4GALT1 complexes
• Tissue-specific substrate specificity uncharacterized
• Catalytic versus non-catalytic functions not genetically separated in vivo